ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Resistance ofPathogens (Basel, Switzerland) · 2025Pooled it
- Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug ResistantInfectious disorders drug targets · 2024Pooled it
- Case Commentary: When susceptibility is not enough in recurrentAntimicrobial agents and chemotherapy · 2026Article
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Disarming carbapenemase-producingAntimicrobial agents and chemotherapy · 2026Article
- Antimicrobial activity of sulbactam-durlobactam againstMicrobiology spectrum · 2026Article
- Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Molecular Compatibility in Chinese Medicine for Cancer Treatment and Drug Development: From Traditional Wisdom to Innovative Therapeutics.Chinese journal of integrative medicine · 2026Article
- Comparative in vitro analysis of sulbactam-durlobactam against extensively drug resistant (XDR) and non-XDR carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates collected from a tertiary care facility in North India.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A 4-methyl-substituted durlobactam analogue as a potential class-D oxacillinase inhibitor inFrontiers in bioinformatics · 2026Article
- Successful Treatment of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Establishment of epidemiological cut-off values of cefotaxime-sulbactam againstFrontiers in microbiology · 2026Article
- Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistantJAC-antimicrobial resistance · 2025Article
- β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2025Review
- Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms.The Journal of antimicrobial chemotherapy · 2025Article
- Combinations comprising dual β-lactams and a β-lactamase inhibitor achieve optimal synergistic inhibition ofAntimicrobial agents and chemotherapy · 2025Article
- Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators againstAntimicrobial agents and chemotherapy · 2025Article
- Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?Antimicrobial agents and chemotherapy · 2025Article
- The Mortality of Colistin MonotherapyInfection & chemotherapy · 2025Article
- Breakthrough Advances in Beta-Lactamase Inhibitors: New Synthesized Compounds and Mechanisms of Action Against Drug-Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination in late-stage development for the treatment of Acinetobacter infections, including those caused by multidrug-resistant strains. Durlobactam is a member of the diazabicyclooctane class of β-lactamase inhibitors with broad-spectrum serine β-lactamase activity. Sulbactam is a first-generation, narrow-spectrum β-lactamase inhibitor that also has intrinsic antibacterial activity against Acinetobacter spp. due to its ability to inhibit penicillin-binding proteins 1 and 3. The clinical utility of sulbactam for the treatment of contemporary Acinetobacter infections has been eroded over the last decades due to its susceptibility to cleavage by numerous β-lactamases present in this species. However, when combined with durlobactam, the activity of sulbactam is restored against this problematic pathogen. The following summary describes what is known about the molecular drivers of activity and resistance as well as results from surveillance and in vivo efficacy studies for this novel combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.